Supplementary Materials

Supplementary Material for:

A technology platform to assess multiple cancer agents simultaneously within a patient's tumor

Richard A. Klinghoffer,* S. Bahram Bahrami, Beryl A. Hatton, Jason P. Frazier, Alicia Moreno-Gonzalez, Andrew D. Strand, William S. Kerwin, Joseph R. Casalini, Derek J. Thirstrup, Sheng You, Shelli M. Morris, Korashon L. Watts, Mandana Veiseh, Marc O. Grenley, Ilona Tretyak, Joyoti Dey, Michael Carleton, Emily Beirne, Kyle D. Pedro, Sally H. Ditzler, Emily J. Girard, Thomas L. Deckwerth, Jessica A. Bertout, Karri A. Meleo, Ellen H. Filvaroff, Rajesh Chopra, Oliver W. Press, James M. Olson*

*Corresponding author. E-mail: rich.klinghoffer{at} (R.A.K.); jolson{at} (J.M.O.)

Published 22 April 2015, Sci. Transl. Med. 7, 284ra58 (2015)
DOI: 10.1126/scitranslmed.aaa7489

This PDF file includes:

  • Methods
  • Fig. S1. The inverse relationship of hypoxic and vascularized tumor regions quantified by CIVO Analyzer.
  • Fig. S2. CIVO outcomes correlate with long-term response to vincristine in primary, patient-derived diffuse large B cell lymphoma.
  • Fig. S3. Intratumoral doxorubicin autofluorescence is detectable with IVIS imaging after microinjection.
  • Fig. S4. Co-microinjection of vincristine and prednisolone enhances the cell death response induced by vincristine alone.
  • Fig. S5. A CIVO-enabled in vivo screen of oncology therapies identifies a dependence on mTOR signaling in Res-Ramos tumors.
  • Table S1. Drug biodistribution after CIVO microinjection of radiolabeled compounds.
  • Table S2. Drug efflux pump expression in Ramos and Res-Ramos cells.
  • Table S3. The top five CIVO drug-screening hits were determined using CC3.
  • Table S4. Patients’ pain experience.
  • Table S5. Stakeholders’ input on the early CIVO prototype.
  • References (2736)

[Download PDF]